ANI Pharmaceuticals completes acquisition of Alimera Sciences
September 17th 2024The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with significant growth potential, expanding ANI’s foothold in strategic therapeutic area of ophthalmology.
Prevent Blindness kicks of 4th annual Inflammatory Eye Disease Awareness Week
September 16th 2024Prevent Blindness is offering free resources to help educate the public and allied healthcare professionals on the many types of inflammatory eye diseases, and steps that should be taken to prevent vision loss.
Retina Society 2024: 12-month outcomes of FARETINA and FARWIDE studies
September 14th 2024Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the 12-month outcomes of the FARETINA and FARWIDE studies from the Retina Society meeting being held this year in Lisbon, Portugal.
Study: 100x improvement in sight detected after gene therapy trial
September 13th 2024According to research conducted by investigators at the Perelman School of Medicine at the University of Pennsylvania School of Medicine, patients with a rare inherited disease affecting their sight experienced quick vision improvements that sustained for the full year-long study.
Polaris Program enlists professors to study vision changes in astronauts
September 11th 2024Prem Subramanian, MD, PhD, a professor of ophthalmology at the Sue Anschutz-Rodgers Eye Center, will use high-tech ocular equipment to monitor the four-member Polaris Dawn crew to investigate why eyes change in space.